Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283266> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4379283266 endingPage "e16173" @default.
- W4379283266 startingPage "e16173" @default.
- W4379283266 abstract "e16173 Background: As far, no data has been published about later-line application of atezolizumab plus bevacizumab (T+A) in patients with unresectable hepatocellular carcinoma (uHCC). Methods: We retrospectively recruited uHCC patients who treated with later-line T+A. Efficacy endpoints included overall survival (OS) and progression free survival (PFS), in accordance with RECIST v1.1. Safety was evaluated with CTCAE v5.0. We also continually enrolled uHCC patients who received later-line regorafenib plus PD-1 inhibitors (Reg+PD-1) as a comparison. Results: Total 33 patients were continually included, 12 used T+A and 21 chose Reg+PD-1. Baseline performance status, liver function and BCLC tumor stage were similar between two cohorts. At data cut-off at February 2023, following median following-up at 18.9 months, median OS in cohort T+A and Reg+PD-1 were 8.2 (95%CI: 5.8-10.6) vs 15.6 (95%CI: 7.6-23.6) (p = 0.237). Median PFS in cohort T+A and Reg+PD-1were 5.1 (95%CI: 1.1-9.1) vs 3.5 (95%CI: 2.1-4.9) (p = 0.575). OS rate and PFS rate are listed. None of efficacy endpoints reached statistical difference. All patients suffered from AEs. No AEs-related death occurred. Conclusions: Efficacy and safety of later-line T+A in uHCC patients was similar with those who used regorafenib plus PD-1 inhibitors, which needed to be further confirmed. [Table: see text]" @default.
- W4379283266 created "2023-06-05" @default.
- W4379283266 creator A5003725565 @default.
- W4379283266 creator A5032048736 @default.
- W4379283266 creator A5034758970 @default.
- W4379283266 creator A5035027190 @default.
- W4379283266 creator A5036954160 @default.
- W4379283266 creator A5041358858 @default.
- W4379283266 creator A5055937409 @default.
- W4379283266 creator A5068989611 @default.
- W4379283266 creator A5005219031 @default.
- W4379283266 date "2023-06-01" @default.
- W4379283266 modified "2023-09-25" @default.
- W4379283266 title "Efficacy and safety in unresectable hepatocellular carcinoma using atezolizumab plus bevacizumab in later-line: A retrospective analysis of real-world evidence." @default.
- W4379283266 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e16173" @default.
- W4379283266 hasPublicationYear "2023" @default.
- W4379283266 type Work @default.
- W4379283266 citedByCount "0" @default.
- W4379283266 crossrefType "journal-article" @default.
- W4379283266 hasAuthorship W4379283266A5003725565 @default.
- W4379283266 hasAuthorship W4379283266A5005219031 @default.
- W4379283266 hasAuthorship W4379283266A5032048736 @default.
- W4379283266 hasAuthorship W4379283266A5034758970 @default.
- W4379283266 hasAuthorship W4379283266A5035027190 @default.
- W4379283266 hasAuthorship W4379283266A5036954160 @default.
- W4379283266 hasAuthorship W4379283266A5041358858 @default.
- W4379283266 hasAuthorship W4379283266A5055937409 @default.
- W4379283266 hasAuthorship W4379283266A5068989611 @default.
- W4379283266 hasConcept C121608353 @default.
- W4379283266 hasConcept C126322002 @default.
- W4379283266 hasConcept C126894567 @default.
- W4379283266 hasConcept C141071460 @default.
- W4379283266 hasConcept C143998085 @default.
- W4379283266 hasConcept C167135981 @default.
- W4379283266 hasConcept C168563851 @default.
- W4379283266 hasConcept C203092338 @default.
- W4379283266 hasConcept C2775949291 @default.
- W4379283266 hasConcept C2776248978 @default.
- W4379283266 hasConcept C2776694085 @default.
- W4379283266 hasConcept C2777701055 @default.
- W4379283266 hasConcept C2777802072 @default.
- W4379283266 hasConcept C2778019345 @default.
- W4379283266 hasConcept C2780057760 @default.
- W4379283266 hasConcept C526805850 @default.
- W4379283266 hasConcept C71924100 @default.
- W4379283266 hasConcept C72563966 @default.
- W4379283266 hasConcept C90924648 @default.
- W4379283266 hasConceptScore W4379283266C121608353 @default.
- W4379283266 hasConceptScore W4379283266C126322002 @default.
- W4379283266 hasConceptScore W4379283266C126894567 @default.
- W4379283266 hasConceptScore W4379283266C141071460 @default.
- W4379283266 hasConceptScore W4379283266C143998085 @default.
- W4379283266 hasConceptScore W4379283266C167135981 @default.
- W4379283266 hasConceptScore W4379283266C168563851 @default.
- W4379283266 hasConceptScore W4379283266C203092338 @default.
- W4379283266 hasConceptScore W4379283266C2775949291 @default.
- W4379283266 hasConceptScore W4379283266C2776248978 @default.
- W4379283266 hasConceptScore W4379283266C2776694085 @default.
- W4379283266 hasConceptScore W4379283266C2777701055 @default.
- W4379283266 hasConceptScore W4379283266C2777802072 @default.
- W4379283266 hasConceptScore W4379283266C2778019345 @default.
- W4379283266 hasConceptScore W4379283266C2780057760 @default.
- W4379283266 hasConceptScore W4379283266C526805850 @default.
- W4379283266 hasConceptScore W4379283266C71924100 @default.
- W4379283266 hasConceptScore W4379283266C72563966 @default.
- W4379283266 hasConceptScore W4379283266C90924648 @default.
- W4379283266 hasIssue "16_suppl" @default.
- W4379283266 hasLocation W43792832661 @default.
- W4379283266 hasOpenAccess W4379283266 @default.
- W4379283266 hasPrimaryLocation W43792832661 @default.
- W4379283266 hasRelatedWork W2938267598 @default.
- W4379283266 hasRelatedWork W3084251940 @default.
- W4379283266 hasRelatedWork W3086685948 @default.
- W4379283266 hasRelatedWork W3166462580 @default.
- W4379283266 hasRelatedWork W4200240365 @default.
- W4379283266 hasRelatedWork W4281682363 @default.
- W4379283266 hasRelatedWork W4283781184 @default.
- W4379283266 hasRelatedWork W4307503407 @default.
- W4379283266 hasRelatedWork W4313045766 @default.
- W4379283266 hasRelatedWork W4318925300 @default.
- W4379283266 hasVolume "41" @default.
- W4379283266 isParatext "false" @default.
- W4379283266 isRetracted "false" @default.
- W4379283266 workType "article" @default.